← Back to Search

Quality Improvement Program

Quality Improvement Program for COPD (PREVAIL Trial)

N/A
Recruiting
Research Sponsored by Observational and Pragmatic Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during implementation and outcome evaluation period, 2.5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a quality improvement and clinical decision support package can improve outcomes for patients with modifiable high-risk chronic obstructive pulmonary disease.

Who is the study for?
This trial is for Primary Care Teams (PCTs) managing patients with high-risk chronic obstructive pulmonary disease (COPD). PCTs must not be involved in other COPD studies, planning to change their electronic health records provider or ownership during the study, and should be willing to potentially use a new quality improvement program.
What is being tested?
The trial is testing the CONQUEST Quality Improvement Program over three years. It compares how well this program works against usual care for patients with modifiable high-risk COPD. Teams are randomly chosen to either start with CONQUEST or continue regular care before getting the program later.
What are the potential side effects?
Since this trial focuses on a quality improvement program rather than a medication, it does not have traditional side effects. However, there may be indirect impacts on patient care processes and outcomes which will be monitored throughout the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during implementation and outcome evaluation period, 2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and during implementation and outcome evaluation period, 2.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
1a: COPD Exacerbations and 1b) major cardiac or respiratory events
Secondary study objectives
Systemic corticosteroid use (SCS)
Other study objectives
Exploratory Objective 1: The rate of explanatory diagnoses other than COPD
Exploratory Objective 2: Lung function
Exploratory Objective 3: Health status

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Delayed Intervention ArmExperimental Treatment1 Intervention
The CONQUEST quality improvement program will be rolled-out to the delayed intervention practices at the end of the outcome evaluation period.
Group II: CONQUEST Intervention ArmExperimental Treatment1 Intervention
Intervention arm clusters will receive the CONQUEST quality improvement program.

Find a Location

Who is running the clinical trial?

Observational and Pragmatic Research InstituteLead Sponsor
The DARTNet Institute (DI)UNKNOWN
AstraZenecaIndustry Sponsor
4,403 Previous Clinical Trials
289,124,883 Total Patients Enrolled

Media Library

CONQUEST Quality Improvement Program (Quality Improvement Program) Clinical Trial Eligibility Overview. Trial Name: NCT05306743 — N/A
Chronic Obstructive Pulmonary Disease Research Study Groups: CONQUEST Intervention Arm, Delayed Intervention Arm
Chronic Obstructive Pulmonary Disease Clinical Trial 2023: CONQUEST Quality Improvement Program Highlights & Side Effects. Trial Name: NCT05306743 — N/A
CONQUEST Quality Improvement Program (Quality Improvement Program) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05306743 — N/A
~40 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top